Skip to main content
KISSEI PHARMACEUTICAL CO.,LTD. logo

KISSEI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4547 ISIN · JP3240600001 T Manufacturing
Open in API
Filings indexed 82 across all filing types
Latest filing 2025-06-24 Annual Report
Country JP Japan
Listing T 4547

About KISSEI PHARMACEUTICAL CO.,LTD.

https://www.kissei.co.jp/e_contents/

Kissei Pharmaceutical Co., Ltd. is a research-driven company engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The company concentrates its research and development investments in key therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its broader product portfolio also addresses conditions in metabolic and endocrinological, obstetrics and gynecological, and ophthalmic fields. Committed to creating innovative medicines, Kissei aims to contribute to global health by addressing unmet medical needs. The company also operates in the health foods sector.

Recent filings

Filing Released Lang Actions
有価証券報告書－第80期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains a header specifying the fiscal year (April 1, 2024, to March 31, 2025), the filing date (June 24, 2025), and extensive XBRL-like metadata tags typical of official annual financial filings submitted to the Kanto Local Finance Bureau. FY 2025
2025-06-24 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is titled "自己株券買付状況報告書" (Report on the Status of Treasury Stock Acquisition) and references Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の６第１項). It details the acquisition of treasury stock (自己株式) during a specific reporting period (May 1, 2025, to May 31, 2025). This specific reporting requirement for share repurchases falls under the category of transactions in a company's own shares. The closest matching definition is 'Transaction in Own Shares' (Code: POS).
2025-06-11 Japanese
大量保有報告書
Major Shareholding Notification Classification · 100% confidence The document explicitly states its title multiple times: "株券等の大量保有の状況の開示に関する内閣府令 第一号様式 大量保有報告書" (Cabinet Office Ordinance on Disclosure of Large Volume Shareholdings Form No. 1 Large Volume Report). This document details the ownership status of shares by Kissei Pharmaceutical Co., Ltd. in Alpico Holdings Co., Ltd., including the number of shares held (4,000,000 shares, 5.41% ownership) and details about any agreements or funding sources. This type of filing in Japan, reporting ownership exceeding 5% of a listed company's shares, is a specific regulatory disclosure. Among the provided codes, there is no direct equivalent for a Japanese 'Large Volume Report' (大量保有報告書). However, this filing concerns a change in significant share ownership, which aligns conceptually with the definition of 'Major Shareholding Notification' (MRQ). It is a mandatory disclosure regarding ownership thresholds, not a general earnings release (ER), annual report (10-K), or management discussion (MDA). Therefore, MRQ is the most appropriate classification.
2024-12-27 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document header explicitly states the filing type as "自己株券買付状況報告書" (Report on the Status of Treasury Stock Acquisition). The legal basis cited is Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act. The content details the acquisition and subsequent disposition (including cancellation/retiring) of treasury stock during the reporting period (November 1 to November 30, 2024). This specific reporting requirement for share repurchases aligns directly with the definition of a Transaction in Own Shares report, which corresponds to the code POS (Transaction in Own Shares).
2024-12-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (Kakuninsho) filed under the Financial Instruments and Exchange Act in Japan. It serves as an officer certification confirming the accuracy of a previously filed semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 80
2024-11-13 Japanese
半期報告書－第80期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Kissei Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis (MDA), and corporate information for the interim period (April 1, 2024, to September 30, 2024). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements, it is classified as an Interim/Quarterly Report. H1 2025
2024-11-13 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.